百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组

证券之星05-12

百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2634529442?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-12 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634529442","market":"sh","top_or_hot":-1,"title":"百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/688506\">百利天恒</a>(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-12 17:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026051200029763.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026051200029763.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688506","symbol_name":"百利天恒","start_time":0,"source_url":"https://stock.stockstar.com/RB2026051200029763.shtml","article_id":"2634529442","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634529442","pubTimestamp":1778578101,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","688506":"百利天恒","02615":"百利天恒","BK0239":"医药制造"},"translate_title":"Baili Tianheng's latest announcement: T-Bren for injection for first-line HER2-positive breast cancer phase III clinical trial completed the first subject enrollment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1.5,"688506":1.5,"02615":1.5},"content_text":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634529442","isCrawlerRequest":true}